We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Find out about coronavirus (COVID-19) treatments available outside of hospital, including information on free prescriptions and lateral flow tests.
How to use a cost utility analysis to evaluate your digital health product.
Section (4A.01 - 4A.31) last updated October 2023.
The CMA acts to help NHS patients access combination therapies used to treat serious medical conditions.
Patentability.
This is a summary of analysis on the costs and savings to public services from those receiving treatment for opiate dependence.
Barriers to innovation in medicines and medicinal technology and the opportunities for improvement: a study by Deloitte and partners.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).